Mugenbio
MUGENBIO is a Swiss medtech startup based in Zurich focused on innovating prostate cancer diagnostics. They are developing a next-generation diagnostic platform that integrates three key innovations: a novel ultra-sensitive molecular quantification method for numerous biomarkers, a powerful diagnostic device capable of quickly and inexpensively quantifying over 100 biomarkers, and smart AI data analytics for more accurate prostate cancer recognition. This platform aims to enable earlier detection, more accurate diagnosis, higher treatment efficacy, and reduce unnecessary biopsies, potentially saving hundreds of thousands of lives annually worldwide. The company operates with a comprehensive R&D strategy to democratize early and accurate prostate cancer detection, positioning itself as a disruptive force in male cancer diagnostics.
Mugenbio
MUGENBIO is a Swiss medtech startup based in Zurich focused on innovating prostate cancer diagnostics. They are developing a next-generation diagnostic platform that integrates three key innovations: a novel ultra-sensitive molecular quantification method for numerous biomarkers, a powerful diagnostic device capable of quickly and inexpensively quantifying over 100 biomarkers, and smart AI data analytics for more accurate prostate cancer recognition. This platform aims to enable earlier detection, more accurate diagnosis, higher treatment efficacy, and reduce unnecessary biopsies, potentially saving hundreds of thousands of lives annually worldwide. The company operates with a comprehensive R&D strategy to democratize early and accurate prostate cancer detection, positioning itself as a disruptive force in male cancer diagnostics.